Sugi Predict

Sugi Predict / Compounds / SCHEMBL14768585

SCHEMBL14768585

SCHEMBL14768585

Cc1cc(Cl)cc(Sc2ccc(C#N)cc2CN2CCC(F)CC2)c1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 5/20 0.38
▸ DRD2 P14416 3/20 0.36
▸ DRD4 P21917 3/20 0.36
▸ DRD3 P35462 3/20 0.36
▸ GPR6 P46095 2/20 0.35
▸ HTR1A P08908 1/20 0.34
▸ HTR3A P46098 1/20 0.34
▸ ADORA2A P29274 1/20 0.34
▸ ADORA1 P30542 1/20 0.34
▸ CXCR3 P49682 1/20 0.34
▸ SLC6A4 P31645 2/20 0.33
▸ HRH3 Q9Y5N1 2/20 0.33
▸ CCR5 P51681 1/20 0.33
▸ SLC6A2 P23975 1/20 0.33
▸ SLC6A3 Q01959 1/20 0.33
▸ USP14 P54578 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14768591 0.92 ACHE (0.38) KDM1ADRD2DRD4DRD3GPR6
SCHEMBL14768623 0.89 CYP2A13 (0.40) DRD2DRD4DRD3ADORA2AADORA1
SCHEMBL14768607 0.89 CHRNA7 (0.39) DRD2DRD4DRD3HTR1AHTR3A
SCHEMBL14768596 0.87 L3MBTL1 (0.38) DRD2DRD4DRD3GPR6HTR1A
SCHEMBL14768622 0.85 KMT2A (0.40) KDM1ADRD2DRD4DRD3HTR1A
SCHEMBL14768590 0.84 ACHE (0.41) KDM1ADRD2DRD4DRD3HRH3
SCHEMBL14768595 0.84 MEN1 (0.35) DRD2DRD4DRD3HTR1AHTR3A
SCHEMBL14039266 0.83 MLNR (0.39) KDM1ADRD2DRD4DRD3HTR1A
SCHEMBL14039315 0.83 DRD4 (0.34) DRD2DRD4DRD3HTR1AHTR3A
SCHEMBL14768592 0.81 CYP2A13 (0.40) KDM1ADRD2DRD4DRD3ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160031841-A1 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS AXIKIN PHARMACEUTICALS, INC. 2016-02-04 — — US disclosed
US-9187425-B2 2,5-disubstituted arylsulfonamide CCR3 antagonists AXIKIN PHARMACEUTICALS, INC. (US) 2015-11-17 — — US disclosed
US-20140066446-A1 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS AXIKIN PHARMACEUTICALS, INC. (US) 2014-03-06 — — US disclosed
US-8563544-B2 2,5-disubstituted arylsulfonamide CCR3 antagonists AXIKIN PHARMACEUTICALS, INC. (US) 2013-10-22 — — US disclosed
US-20130065889-A1 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS AXIKIN PHARMACEUTICALS, INC. (US) 2013-03-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160031841-A1 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS CCR3, CCR1, CCR4 KDM1A 3074/4885DRD2 1856/4885DRD4 2939/4885
US-20140066446-A1 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS CCR3, CCR1, CCR4 KDM1A 3074/4885DRD2 1856/4885DRD4 2939/4885
US-20130065889-A1 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS CCR3, CCR1, CCR4 KDM1A 3074/4885DRD2 1856/4885DRD4 2939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.